041960 - Komipharm International Co., Ltd.

041960 Summary

Biopharma

Stock Price & Overview

₩9,710 +330 (+3.52%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩9,710 ≈ US$7 · Market cap ₩0.7tn (≈ $512m)

041960 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	52.5	58.8	42.6	39.8	35.8	37.2	35.5	35.0	36.6	37.6	36.4
Cost of Revenue	35.4	37.0	30.0	28.3	24.6	23.8	24.1	25.2	25.0	26.7	25.4
Gross Profit	17.1	21.8	12.7	11.5	11.2	13.4	11.4	9.8	11.6	11.0	11.0
Selling, General & Administrative	15.1	15.6	18.9	15.3	16.5	15.6	16.9	16.0	11.7	10.4	11.6
Operating Income	2.0	6.2	-6.3	-3.8	-5.3	-2.2	-5.4	-6.2	-0.1	0.6	-0.6
Finance Income	1.8	2.9	3.2	0.2	0.1	0.2	0.4	0.3	0.5	0.1	0.2
Finance Costs	10.4	4.0	2.8	2.2	1.7	1.5	1.9	1.1	1.3	1.5	1.4
Pretax Income	-7.9	14.7	-5.7	-7.5	-5.9	-4.0	-13.9	-19.1	-7.8	-0.1	-9.4
Income Tax Expense	0.1	0.0	0.2	0.0	0.0	0.0	9.4	3.5	2.6	-0.3	-2.8
Net Income	-8.0	14.7	-5.9	-7.5	-5.9	-4.0	-23.3	-15.5	-5.2	0.2	-6.5
Total Comprehensive Income	-7.6	15.3	-5.4	-7.3	-5.8	-3.7	-22.8	-16.7	-6.1	0.1	-6.3

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	133.9	122.8	118.6	111.8	115.3	121.9	125.6	139.9	149.3	149.8	133.4
Current Assets	68.5	59.9	50.0	42.6	41.5	44.7	46.9	48.7	53.6	52.3	43.6
Cash & Cash Equivalents	27.9	12.4	14.8	10.8	12.0	15.0	18.9	19.2	27.6	26.8	12.9
Inventories	15.2	14.6	14.9	16.3	14.2	13.8	12.3	13.2	11.9	11.3	11.2
Trade Receivables	23.2	21.9	18.0	14.1	12.8	13.0	13.2	12.8	13.0	12.7	13.8
Non-current Assets	65.4	62.8	68.6	69.1	73.8	77.2	78.7	91.2	95.6	97.5	89.8
Property, Plant & Equipment	55.8	55.8	64.2	66.5	70.1	72.1	73.7	71.7	70.3	72.0	66.1
Intangible Assets	5.6	3.9	1.2	0.8	0.9	0.7	0.8	3.6	14.0	20.9	19.0
Total Liabilities	61.9	57.2	58.6	46.1	42.9	43.8	49.5	41.9	42.0	50.5	57.3
Current Liabilities	52.8	46.2	52.2	41.0	25.7	39.3	31.0	37.9	36.1	36.9	26.9
Non-current Liabilities	9.1	11.0	6.4	5.1	17.2	4.5	18.4	4.0	5.9	13.6	30.3
Total Equity	72.1	65.5	60.0	65.6	72.4	78.1	76.2	98.0	107.3	99.3	76.1
Share Capital	7.4	7.1	7.1	6.4	6.4	6.4	6.4	5.5	5.5	5.5	5.4
Retained Earnings	-17.9	-10.7	-23.8	-24.8	-18.3	-13.8	-27.0	-18.7	-4.0	1.1	0.5

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	-0.6	8.8	-2.8	-1.8	-1.3	0.0	1.0	-2.0	0.2	1.2	-2.9
Cash from Investing Activities	5.8	2.0	-3.5	-1.4	-0.7	-1.6	-6.6	-12.3	0.8	-6.6	-6.0
Purchase of Property, Plant & Equipment	3.1	1.0	0.6	0.8	0.8	1.7	5.7	5.4	2.7	9.1	7.5
Cash from Financing Activities	10.2	-13.2	10.5	2.0	-1.0	-1.6	5.4	7.2	0.3	19.0	15.2
Net Change in Cash	15.4	-2.4	4.2	-1.1	-3.0	-3.2	-0.3	-7.2	1.4	13.6	6.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	16.7	11.9	11.9	12.5	13.7	14.4	15.7	11.0	19.2	12.9
Cost of Revenue	10.0	7.4	8.4	8.7	8.6	9.7	11.4	7.1	10.6	7.9
Gross Profit	6.7	4.6	3.5	3.7	5.1	4.7	4.3	3.9	8.6	5.0
Selling, General & Administrative	5.1	4.3	3.7	3.7	3.5	4.2	4.0	3.0	4.6	4.1
Operating Income	1.6	0.3	-0.2	0.1	1.6	0.5	0.4	0.9	4.0	1.0
Finance Income	0.7	0.2	1.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1
Finance Costs	2.3	0.6	4.1	0.9	4.5	0.8	0.9	0.8	0.8	0.8
Pretax Income	0.5	0.7	-4.2	-0.3	-3.3	-0.1	0.2	8.9	4.8	0.7
Income Tax Expense	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	—	—
Net Income	0.5	0.7	-4.3	-0.3	-3.3	-0.1	0.2	8.9	4.8	0.7
Total Comprehensive Income	0.7	1.3	-4.0	0.1	-3.7	-0.0	0.2	9.0	5.6	0.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	139.1	134.4	133.9	133.7	121.7	122.8	122.8	132.6	123.0	115.6
Current Assets	71.8	67.9	68.5	69.0	59.0	60.1	59.9	69.8	59.6	51.4
Cash & Cash Equivalents	21.4	18.6	27.9	25.5	19.0	16.0	12.4	27.5	12.1	10.2
Inventories	16.2	15.8	15.2	15.3	15.3	14.6	14.6	17.2	14.4	14.3
Trade Receivables	25.3	25.2	23.2	24.0	23.2	23.7	21.9	21.4	23.7	18.5
Non-current Assets	67.3	66.5	65.4	64.7	62.7	62.7	62.8	62.7	63.4	64.2
Property, Plant & Equipment	56.9	56.6	55.8	55.5	55.0	55.4	55.8	57.3	57.9	57.8
Intangible Assets	6.8	6.1	5.6	4.9	4.5	4.0	3.9	3.5	3.4	3.3
Total Liabilities	65.0	61.1	61.9	58.8	50.8	57.3	57.2	61.3	59.3	55.1
Current Liabilities	55.0	52.0	52.8	33.9	38.9	46.3	46.2	53.3	51.2	48.8
Non-current Liabilities	10.0	9.2	9.1	24.9	11.9	11.0	11.0	8.0	8.1	6.3
Total Equity	74.2	73.3	72.1	74.9	70.8	65.5	65.5	71.3	63.7	60.5
Share Capital	7.4	7.4	7.4	7.3	7.3	7.1	7.1	7.1	7.1	7.1
Retained Earnings	-16.4	-17.0	-17.9	-14.0	-13.8	-10.6	-10.7	-11.4	-17.9	-23.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	1.7	-1.5	0.9	-0.2	-0.5	-0.9	3.1	1.9	1.8	2.0
Cash from Investing Activities	0.0	-7.0	1.7	-4.3	4.0	4.5	-11.3	15.3	-0.4	-1.6
Purchase of Property, Plant & Equipment	0.5	0.4	1.7	0.8	0.5	0.1	0.5	0.2	0.2	0.2
Cash from Financing Activities	0.8	-1.2	-0.2	10.9	-0.4	-0.1	-7.1	-1.6	0.6	-5.1
Net Change in Cash	2.6	-9.7	2.4	6.4	3.1	3.5	-15.3	15.5	2.0	-4.6

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

041960 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	52.5	-10.7%	+9.6%	+7.1%	+3.7%
Operating income	2.0	-68.3%	—	—	—
Net income	-8.0	—	—	—	—
EPS	₩-109	—	—	—	—
Operating cash flow	-0.6	—	—	—	—
Shareholders' equity	72.1	+9.9%	+3.2%	-1.6%	-0.5%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

041960 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	32.5%	37.0%	29.7%	28.8%	31.3%	36.0%
Operating margin	3.7%	10.5%	-14.7%	-9.6%	-14.8%	-5.9%
Net margin	-15.3%	25.0%	-13.9%	-18.8%	-16.6%	-10.6%
Return on equity	-11.7%	23.4%	-9.4%	-10.8%	-7.9%	-5.1%
Return on assets	-6.3%	12.2%	-5.1%	-6.6%	-5.0%	-3.2%
Operating cash flow / revenue	-1.2%	15.1%	-6.6%	-4.5%	-3.5%	0.1%
Capex / revenue	5.9%	1.8%	1.5%	2.1%	2.3%	4.5%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 041960

Symbol	Last Price
185750Chong Kun Dang Pharmaceutical Corp.	₩68,000 -0.3%
115180Qurient Co., Ltd.	₩23,050 +17.3%
476830Rznomics, Inc.	₩28,200 +6.8%
003850Boryung Corporation	₩9,040 +1.6%
950260Ingenia Therapeutics Inc.(reg.s)	₩15,580 -1.5%
085660Chabiotech Co., Ltd.	₩8,090 +2.1%
476060Onconic Therapeutics, Inc.	₩16,440 -3.9%
317450Myungin Pharm	₩44,650 +0.0%
001060JW Pharmaceutical	₩27,500 +1.3%
456160G2GBIO, Inc.	₩37,950 +5.7%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.